Lend your voice. Join us by sending a letter to let Congress know you want to see the end of AIDS in 2030, requiring their support to fully fund PEPFAR. This isn’t just the smart thing to do, for ...
Dr. Lisa Abuogi, an associate professor in the Department of Pediatrics at the University of Colorado and the medical ...
She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...
Stock Levels: A recent national stock-level assessment indicates that there are at least two months of stock at facilities and five months at central warehouses. This is consistent with normal ...
So far, many foundational global health efforts to treat malnutrition, prevent newborn and maternal mortality, or eliminate infectious diseases such as HIV, malaria, tuberculosis, malnutrition ...
This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...
Whether you’re moving locally or heading to another state or country, a solid moving budget helps you avoid surprises and keep costs in check. Start planning your moving budget at least eight ...
The health budget is projected to grow to 329 billion rand by 2027/28, and the department has to find money for HIV/AIDS initiatives. Mark Heywood, Co-founder and member of the Board of Directors ...
According to an analysis by the United Nations AIDS agency, UNAIDS, a long-term loss of PEPFAR funding would lead to a 10-fold increase in HIV-related deaths globally, costing around 6.3 million ...
The US has supported HIV/Aids programmes in South Africa through the President’s Emergency Plan for Aids Relief (Pepfar). The health department drew 17% of the budget for its HIV programme from ...
a review of over half a million children receiving HIV treatment through US-funded PEPFAR programmes shows. The findings were presented at the Conference on Retroviruses and Opportunistic Infections ...
An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet, external medical journal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results